Company / Operating Cash Flow per Share
BioMarin Pharmaceutical Operating Cash Flow per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
$4.31
FY2025
5-year range
$0.84 / $4.31
FY2021-FY2025
Trend
+43.4%
vs FY2024
Sector context
#25 of 212
Health Care
What the data says
BioMarin Pharmaceutical's operating cash flow per share of $4.31 is higher than 88% of companies in the Health Care sector (FY2025). Improved from $0.84 to $4.31 over the past 2 years.
Based on SEC 10-K filings.
4.31 in FY2025 with a 5-year CAGR of +55.8%. Top quartile in the Health Care sector.
Improved from $0.84 to $4.31 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- +65.8%
- 5-Year CAGR
- +55.8%
- 10-Year CAGR
- -
Sector benchmark
Top 12% in Health CareTop 12% of 212This company $4.31 Sector average -$14.72
▼
+129.2% above sector average
Key checks
Key Insights
- In FY2025, operating cash flow per share increased 43.4% year-over-year.
- Ranks #25 out of 212 companies in the Health Care sector.
- Lowest operating cash flow per share in the period was in FY2016.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.31 | +43.4% |
| FY2024 | $3.00 | +255.6% |
| FY2023 | $0.84 | -10.6% |
| FY2022 | $0.94 | -43.6% |
| FY2021 | $1.68 | +256.7% |
| FY2020 | $0.47 | +75.0% |
| FY2019 | $0.27 | +136.7% |
| FY2018 | $0.11 | +327.6% |
| FY2017 | -$0.05 | +96.2% |
| FY2016 | -$1.32 | +2.9% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026